The zebrafish as a model for studying neuroblastoma by Corallo, Diana et al.
Corallo et al. Cancer Cell Int  (2016) 16:82 
DOI 10.1186/s12935-016-0360-z
REVIEW
The zebrafish as a model for studying 
neuroblastoma
Diana Corallo1*, Simona Candiani2, Michela Ori3, Sanja Aveic1 and Gian Paolo Tonini1
Abstract 
Neuroblastoma is a tumor arising in the peripheral sympathetic nervous system and is the most common cancer 
in childhood. Since most of the cellular and molecular mechanisms underlying neuroblastoma onset and progres-
sion remain unknown, the generation of new in vivo models might be appropriate to better dissect the peripheral 
sympathetic nervous system development in both physiological and disease states. This review is focused on the use 
of zebrafish as a suitable and innovative model to study neuroblastoma development. Here, we briefly summarize the 
current knowledge about zebrafish peripheral sympathetic nervous system formation, focusing on key genes and cel-
lular pathways that play a crucial role in the differentiation of sympathetic neurons during embryonic development. 
In addition, we include examples of how genetic changes known to be associated with aggressive neuroblastoma 
can mimic this malignancy in zebrafish. Thus, we note the value of the zebrafish model in the field of neuroblastoma 
research, showing how it can improve our current knowledge about genes and biological pathways that contribute 
to malignant transformation and progression during embryonic life.
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Background
Neuroblastoma (NB) is the most common extracranial 
solid tumor arising in the peripheral sympathetic nerv-
ous system (PSNS), including spinal sympathetic gan-
glia and the adrenal medulla [1]. This devastating tumor 
originates from the sympathoadrenal cell lineage deriv-
ing from neural crest cells (NCCs) and is responsible for 
approximately 15% of childhood cancer-related mortality 
[2]. NB is characterized by great genetic and biological 
heterogeneity, and many studies have been performed to 
understand the complex mechanisms underlying NB ori-
gin and progression.
Over the past years, zebrafish has become an attrac-
tive alternative tool to the classical mouse model for 
studying many human diseases, spanning from pediat-
ric to adult tumors and from blood to neurodegenera-
tive disorders (for extended reviews, see [3, 4]). Notably, 
several experimental techniques that are applied to mice 
have been extended to zebrafish, and the zebrafish model 
promises to be extremely useful for development of effec-
tive therapeutic strategies for cancer research. For exam-
ple, zebrafish has emerged as an important tool for the 
identification of new chemical compounds with potential 
clinical implications [5], permitting a high-throughput 
screening of currently available chemical libraries [6].
It is important to highlight that a complete understand-
ing of the biological processes underlying zebrafish PSNS 
development will be useful for defining the molecular 
pathways contributing to malignant transformation and 
NB progression. The biological information obtained 
with the zebrafish in vivo model might contribute to the 
discovery of genes and molecular pathways that are dys-
functional during the early stages of NB development.
Neuroblastoma overview
NB presents as either a localized or metastatic disease, 
and patients with NB have varying survival rates. Patients 
with a localized tumor have a good outcome, with an 
overall survival (OS) of more than 99% 5  years after 
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diagnosis. In contrast, the OS of children older than one 
year with a metastatic tumor is less than 40% 5 years after 
diagnosis [7, 8].
A large assortment of copy number variations (CNVs), 
ranging from numerical CNVs in localized tumors to struc-
tural CNVs in metastatic tumors, has been observed in NB. 
The most frequently observed structural CNVs are loss 
of chromosomes 1p, 3p, 4p, 9p, 11q and 14q and gain of 
chromosomes 2p and 17q [9–11]. In the last decade, many 
efforts have been made to identify candidate NB genes. In 
fact, MYCN oncogene amplification, which is observed 
in 20% of patients with NB, plays a role in tumor progres-
sion and aggressiveness [12]. The genomic amplification of 
MYCN is frequently observed in patients who are resist-
ant to any therapy and is currently a prognostic marker 
of risk stratification in patients with NB [13]. Other genes 
have been identified for NB predisposition. ALK (anaplas-
tic lymphoma kinase) was the first gene to be identified as 
a familial NB predisposition gene [14]. Several activating 
mutations have been discovered in the ALK tyrosine kinase 
domain, although mutations F1174L and R1275Q are the 
most frequently observed and are associated with a more 
negative prognosis [15, 16]. Moreover, LMO1 [17], BARD1 
[10] and LINC00340 [18] have been identified by genome-
wide association studies as other NB predisposition genes. 
More recently, a massive whole-genome sequencing 
approach has been used to discover novel key mutations 
in genes involved in NB onset and progression. Pugh et al. 
[19] and Molenaar et al. [20] screened more than 200 cases 
of NB at different clinical stages of the disease and found a 
low frequency of recurrent mutations. Thus, it seems that 
NB originates during embryonic life as result of chromo-
somal instability rather than from a mutation in a single 
NB gene. There is a general agreement that MYCN gene 
amplification plays a major role in driving NB tumorigen-
esis, while ALK gene mutation cooperates with MYCN to 
enforce tumor aggressiveness [21, 22].
The in vivo models of neuroblastoma
Previous studies have established different in vivo mod-
els of NB. Mouse models of NB are clinically relevant 
tools for studying the growth and metastasis of this 
aggressive malignancy. Orthotopic and subcutaneous 
xenograft mouse models have been extensively gener-
ated for the preclinical testing of new therapeutic strat-
egies against NB [23–30]. Notably, the xenograft mouse 
model displays biological features that limit the possi-
bility of obtaining a standardized in vivo system reflect-
ing tumor pathogenesis. These variables include the 
manipulation of tumor cells prior to their engraftment 
outside of the natural tumor microenvironment. Due to 
the imposed and artificial conditions, xenotransplanted 
mice frequently develop tumors that do not represent the 
corresponding human cancer that develops in its native 
environment [31]. Tumor cell manipulation might result 
in genome and/or transcriptomic changes distinct from 
those arising in patients’ cancer cells [31]. To overcome 
these limitations, Weiss and colleagues [32] generated a 
transgenic NB mouse model through the overexpression 
of the human MYCN oncogene in neural crest-derived 
cells driven by the rat tyrosine hydroxylase promoter. 
These mice spontaneously develop NB exclusively in 
the sympathoadrenal system with high resemblance to 
human tumors, demonstrating the involvement of MYCN 
in NB genesis [33–37].
Other transgenic mouse models have helped to elu-
cidate the cellular mechanisms of NB pathogenesis. In 
addition to MYCN gene amplification, the in vivo forced 
expression of genes that are normally involved in sym-
pathoadrenal development during embryonic life (such 
as ALK and LIN28B) drives NB formation [38, 39]. Thus, 
these animal models support the prenatal origin of this 
pediatric cancer. Among the increasing number of models 
dedicated to recapitulating NB origin, the zebrafish model 
has emerged as a novel important platform for perform-
ing in vivo studies of NB pathogenesis. Zebrafish displays 
several logistic advantages that make it an attractive alter-
native for mimicking human diseases: (i) its characteris-
tics of reproduction and transparency will allow the study 
of the first stages of development in a short amount of 
time; (ii) the optical transparency of zebrafish embryos 
and larvae will allow the study of the behavior of engrafted 
human cancer cells or the expression of fluorescently 
tagged oncogenes; (iii) its morphology will allow the study 
of disease phenotypes by following the morphological 
aberrations that often arise in a short amount of time; (iv) 
it is possible to have thousands of zebrafish embryos and 
larvae for tissue specimen collection and high-throughput 
drug screening; (v) an increasing number of technologies 
are available for zebrafish genetic manipulation, such as 
transient/stable gene loss and gain of function as well as 
high-throughput DNA and RNA sequencing techniques. 
Thus, the zebrafish model is a powerful tool for dissect-
ing the molecular pathways involved in PSNS devel-
opment and NB origin. This biological information is 
important not only for understanding exactly when and 
where malignant transformations occur but also for more 
the rapid determination of possible genetic or chemical 
tumor progression modifiers that might guarantee novel 
and more effective therapies.
Zebrafish as a model for studying peripheral 
sympathetic nervous system development
Increasing evidence indicates that NB arises from the 
NCC lineage during embryonic life (for an extended 
review, see [40]); thus, it is crucial to understand the 
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characteristics of NCCs under both normal and patho-
logical conditions in order to dissect the initial tumori-
genesis steps of this embryonic cancer.
The cells of the sympathetic ganglia and mature adrenal 
medulla originate from a transient pool of NCCs. These 
cells pass through four critical developmental phases. 
First, NCCs undergo an epithelial to mesenchymal tran-
sition (EMT) from the most dorsal region of the neural 
tube and differentiate into sympathoadrenal precursors. 
Then, sympathoadrenal precursors migrate toward the 
ventral portion of the notochord near the dorsal aorta. 
Finally, these cells activate the neuronal differentiation 
program, giving rise to the mature sympathetic ganglia 
and chromaffin cells of the adrenal medulla.
Induction of an epithelial to mesenchymal transition 
in neural crest cells
After neurulation, NCCs undergo an EMT from the roof 
plate of the neural tube, delaminating from the neuroepi-
thelium and then migrating through the periphery, where 
they differentiate into several cell types, including cells 
of the peripheral nervous system and enteric nervous 
system, pigmented cells, Schwann cells, adrenal medul-
lary cells, and cartilage cells of the craniofacial skeleton 
[41–43]. The downregulation of cadherins on the cell sur-
face (usually mediated by the upregulation of mesenchy-
mal transcription factors, such as Snail, Slug and Twist), 
cytoskeleton remodeling and the synthesis of proteases 
are key events that mediate this transition. These cellular 
changes are also essential for the development of many 
tissues during embryogenesis. Interestingly, similar mod-
ifications are recapitulated during pathological processes, 
such as fibrosis, cancer and drug resistance [44, 45].
Recently, in vitro studies have suggested that an EMT 
might also be involved in NB progression, and Nozato 
and colleagues [46] found that KRT19, ERBB3, TWIST1 
and TCF3 EMT-related genes are differentially expressed 
in a cohort of patients with NB. Thus, in addition to 
MYCN gene amplification, the expression level of EMT-
related genes might become an additional prognostic 
marker for patients with NB. Despite these recent discov-
eries, there is no solid evidence from studies using in vivo 
models that supports the relationship between EMT 
and NB pathogenesis. Therefore, additional studies will 
be necessary to elucidate whether EMT plays a role in 
tumor development and eventual metastasis in NB. Con-
sequently, the window of time in which EMT impairment 
might lead to the modulation of tumor-associated signals 
should be defined.
Neural crest cell migration and differentiation
After an EMT begins, NCCs acquire a polarized mor-
phology and follow two migratory pathways away from 
the neural tube: the dorsolateral and the ventromedial 
(Fig. 1). NCC-derived sympathoadrenal precursors ven-
tromedially migrate within the sclerotome, whereas the 
dorsolateral pathway mostly generates the pigmented 
cell lineage, including melanocytes [47–49]. Neverthe-
less, in the trunk region, the route of the NCCs and 
their migration schedule are not perfectly mirrored in 
all species but rather show importantly dissimilar pat-
terns among them [50]. Spatially and temporally regu-
lated extrinsic signals from the neural tube, somites, 
notochord and dorsal aorta are essential for the migra-
tion and specification of sympathoadrenal precursors. 
These signals include many permissive factors, such 
as the extracellular matrix proteins laminins, versi-
can and fibronectin, which drive the earliest migrating 
Fig. 1 Patterns of NCC migration in zebrafish. Schematic cartoon 
depicting the two main migratory pathways of NCCs during embry-
onic development (transverse section of a vertebrate embryo). NCCs 
(blue) follow the ventromedial pathway (green arrow) and migrate 
between the neural tube and somites and then bilaterally reach 
the dorsal portion of the dorsal aorta, where they differentiate into 
sympathoadrenal progenitors (green). NCCs that migrate dorsolat-
erally (red arrow) between somites and the overlying ectodermal 
epithelium give rise to pigment cells (red). NCCs neural crest cells, 
EE ectodermal epithelium, NT neural tube, NO notochord, DA dorsal 
aorta, S somite
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sympathoadrenal precursors into the ventromedial path-
way [51–53]. In parallel, ephrins, chondroitin sulfate 
proteoglycans and other inhibitory molecules block the 
alternative dorsolateral pathway.
The molecular development of the peripheral sympathetic 
nervous system in zebrafish
The development of the PSNS in zebrafish has been 
well examined [54, 55]. In fact, despite several struc-
tural and physiological differences between zebrafish 
and mammals, the morphogenesis and differentiation of 
sympathetic neurons in zebrafish are strongly compara-
ble to those of other vertebrates. In zebrafish, trunk sym-
pathoadrenal precursors begin to migrate approximately 
16 h post-fertilization (hpf) from somite 7 and follow the 
ventromedial pathway, indicating that the formation of 
sympathetic neurons is similar to that of other vertebrates 
[54, 55]. NCCs are easily identified by the expression of 
the transcription factor Sox10 [56, 57], and crestin is a 
multicopy retro-element expressed in pre-migratory and 
migratory NCCs (Fig.  2) [58]. Moreover, in mammalian 
embryos, the receptor tyrosine kinase proto-oncogene 
Fig. 2 Expression of crestin in neural crest cells (NCCs) during zebrafish development. a Crestin is expressed in premigratory NCCs in wild-type 
embryos at 19 hpf. b, c Higher magnification images of the embryo in a, showing the streams of migrating NCCs labeled with the crestin probe. d, e 
At 24 hpf, trunk migratory NCCs labeled by crestin (arrowheads) gradually migrated toward the ventral dorsal aorta. f–h Cross sections through the 
levels (f, g, h) shown in d. Streams of trunk NCCs defined by crestin expression migrate between the somite and the neural tube. da dorsal aorta; n 
notochord; s somite; sc spinal cord
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ErbB3 and its dimerization partner ErbB2 are required 
for proper trunk NCC migration. Notably, mice mutated 
in either ErbB display embryonic lethality, limiting their 
use within early developmental stages [59, 60]. Honjo and 
colleagues [61] reported that zebrafish mutants lacking 
ErbB3 or ErbB2 do not form trunk NC-derived sympa-
thetic neurons, whereas cranial NC derivatives appear 
normal. These data suggest that ErbB2/ErbB3 signaling 
is required for trunk NCC migration and localization in 
the embryo within a specific window of time. Moreover, 
Sox10 increases the expression of ErbB3, describing a 
positive activating loop from an intrinsic transcriptional 
factor that can modulate the migration responsiveness of 
cells [62–64]. Interestingly, the proto-oncogene MYCN 
appears to be required for the migration, survival and/or 
differentiation of NCCs that migrate to the dorsal aorta. 
Accordingly, homozygous mutant mouse embryos dis-
play embryonic lethality (at approximately 11.5  days of 
gestation), and several developing organs are affected, 
including the dorsal root ganglia and sympathetic ganglia 
of the PSNS [65–67].
When sympathoadrenal precursors reach the dorsal 
aorta, other molecules, such as N-Cadherin, CXCL12, 
and Ephrins, play a critical role in the initiation of the seg-
mental organization of sympathetic ganglia in a discrete 
and metameric pattern [68]. Moreover, the dorsal aorta-
derived bone morphogenetic factors (BMPs) are essen-
tial for the differentiation of sympathoadrenal precursors 
into mature sympathoadrenal cells. Later, cells destined 
to become chromaffin cells of the adrenal medulla retain 
their responsiveness to BMPs. Consequently, sympa-
thoadrenal precursors continue to migrate toward the 
BMP4-secreting cortical cells of the adrenal cortex and 
finally form the adrenal medulla near the anterior pro-
nephros [69]. The sympathoadrenal lineage is specified 
by a tightly regulated set of transcription factors, and in 
zebrafish, this process has been characterized in detail. 
After reaching the proper location near the dorsal aorta, 
sympathoadrenal precursors begin to express the pan-
neuronal marker 16A11, which comprises members of 
the Hu family of RNA binding proteins [70]. In 2002, An 
and colleagues [54] demonstrated that sympathoadre-
nal cells differentiate from the rostral toward the caudal 
part of the embryo. In fact, cervical neurons develop at 
2  days post-fertilization (dpf) and comprise the supe-
rior cervical ganglion (SCG), whereas trunk sympathetic 
neurons express 16A11 several days later (between 4 and 
8 dpf ). The reason for this delay remains unknown since 
trunk sympathoadrenal precursors reach the dorsal aorta 
between 24 and 36 hpf, when the primary source of BMP 
is still present. Indeed, since NB can develop anywhere 
along the sympathetic axis beside the adrenal medulla, 
it may be relevant to investigate how these cells respond 
differently to BMPs in terms of both space and time [54]. 
Thus, it is likely that NB may arise from earlier crest 
derivatives before the development of the sympathoadre-
nal lineage [1, 71]. This phenomenon could contribute to 
the heterogeneous histology and pathology found among 
NBs.
Other transcription factors are required for sympa-
thoadrenal cell development and maintenance, such as 
phox2b and zash1a, which in turn activate the expres-
sion of hand2 and later markers, such as phox2a, GATA2 
and AP-2 alpha (tfap2a) [72–75]. For example, the hand2 
zebrafish mutant (hands off) fails to reach the complete 
differentiation of sympathoadrenal cells, even though 
some early PSNS markers are normally expressed [74]. 
An analogous phenotype has been observed in mutant 
embryos lacking the tfap2a gene (mount blanc mutants), 
in which sympathoadrenal cells fail to differentiate com-
pletely [76, 77].
Finally, sympathoadrenal cells undergo catecholamin-
ergic terminal differentiation for the formation of the 
mature sympathetic chain and the adrenal gland. This last 
differentiation step requires the expression of tyrosine 
hydroxylase (TH) and dopamine B-hydroxylase (DBH) 
genes, which are involved in the conversion of the amino 
acid l-tyrosine to noradrenalin [78]. In zebrafish, both 
genes are used to detect fully differentiated sympathetic 
neurons. The TH protein is detectable in the superior 
cervical ganglion starting from 2 dpf, whereas its expres-
sion in trunk sympathetic neurons becomes detectable at 
7 dpf (Fig. 3). In general, by 10 dpf, the majority of sympa-
thetic neurons express TH, and the complete maturation 
of sympathetic ganglia and chromaffin cells is reached 
at 28  dpf [54]. Expression protein analysis of DBH dur-
ing sympathetic neuron development shows that DBH is 
detectable 1 day after TH expression [54].
Newly developed high-resolution imaging techniques 
and genetic tools will continue to provide unique insight 
into the mechanisms controlling cell differentiation dur-
ing embryogenesis [79]. Accordingly, the identification 
of new zebrafish mutants affecting PSNS development 
might contribute to the in vivo analysis of NB onset.
Zebrafish genetic models of neuroblastoma
As previously described, several in  vivo strategies have 
been used to dissect the molecular pathways that nor-
mally coordinate sympathetic neuron development. In 
particular, forward and reverse genetic techniques and 
transgenic zebrafish models have provide new insight 
into the function of the genes and pathways involved in 
either normal vertebrate development or human cancer 
formation.
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The proto‑oncogene MYCN: functional interactions 
with ALK receptor and the tumor suppressor NF1
During normal sympathoadrenal development, the 
proto-oncogene MYCN is highly expressed in the early 
post-migratory neural crest cells, where it regulates the 
ventral migration and expansion of NCCs, whereas 
MYCN protein levels gradually decrease in differentiat-
ing sympathetic neurons. This observation suggests that 
sympathoadrenal maturation requires low or absent 
MYCN expression [80, 81]. In zebrafish, the persistent 
expression of the MYCN gene in sympathoadrenal pre-
cursors, which mimics the amplification observed in 
more than 20% of patients with NB, dramatically blocks 
development toward a chromaffin-like cell phenotype, 
leading to NB mass formation in the interrenal gland 
[21, 22]. The tumor formation in the zebrafish inter-
renal gland recapitulates the adrenal medullary site 
of origin that is observed in approximately half of the 
children affected by NB [82]. In contrast, tumors in the 
murine MYCN transgenic model arise predominately 
in the sympathetic cervical ganglia complex and the 
superior cervical ganglia [80, 83]. Tumor masses arising 
in MYCN-overexpressing zebrafish are histologically, 
immunohistochemically and ultrastructurally very simi-
lar to those arising in humans, supporting the use of this 
model to investigate NB tumorigenesis. In addition, both 
the onset and penetrance of this disease are markedly 
enhanced by the co-expression of the transgene encod-
ing the activated ALK receptor tyrosine kinase, carrying 
the most common and aggressive activating mutation, 
F1174L, found in humans [84]. This mutation, although 
not tumorigenic itself in zebrafish, potentiates the 
oncogenic power of MYCN by blocking the apoptosis of 
MYCN-overexpressing sympathoadrenal neuroblasts of 
the interrenal gland [21]. In fact, this double-transgenic 
animal model allowed the elucidation of the molecular 
mechanisms through which MYCN and ALK cooperate 
in the generation of aggressive tumors. Additional studies 
using the zebrafish model will be required to determine 
whether other mutational events can induce NB in a syn-
ergistic way, as in the MYCN-ALK model.
More recently, the zebrafish MYCN transgenic model 
has been used to study which domain of the tumor sup-
pressor protein NF1 is important for inhibiting the 
growth of NB [85]. When He et al. deleted the gene for 
the zebrafish version of NF1, the penetrance and the 
disease onset of MYCN-induced NBs were accelerated 
and associated with the aberrant activation of the RAS-
MAPK signaling. Interestingly, supplying zebrafish with 
the GTPase-activating protein (GAP)-related domain 
(GRD) of NF1 was enough to suppress NB growth. In 
addition, the MEK inhibitor against the RAS-MAPK 
pathway, trametinib, synergizes with, 13-cis retinoic acid, 
to suppress nf1-deficient neuroblastoma in  vivo. These 
findings establish the double-transgenic line nf1-defi-
cient/MYCN-overexpressing zebrafish as a valuable tool 
for testing new therapeutic strategies for NB with muta-
tions affecting the RAS-MAPK pathway, which appear to 
be a major cause of relapse in patients with NB [85].
The homeobox transcription factor PHOX2B
Previous in  vivo models have established PHOX2B as 
a key regulator of autonomic neuron development. In 
fact, PHOX2B mutant mice showed embryonic lethality 
Fig. 3 Expression of TH by fully differentiated sympathetic neurons in zebrafish. a Dorsal view of a wild-type embryo probed at 48 hpf by in situ 
hybridization with TH. At this developmental stage, TH mRNA is expressed by dopaminergic neurons of the ventral diencephalon (hatched box), 
arch-associated catecholaminergic neurons (arrowhead) and neurons constituting the locus coeruleus (arrow). b Higher magnification of dopamin-
ergic neurons stained with the TH probe
Page 7 of 9Corallo et al. Cancer Cell Int  (2016) 16:82 
due to a failure of PSNS formation [86]. Moreover, TH-
MYCN transgenic mice developed NB in early post-
natal sympathetic ganglia predominantly composed of 
PHOX2B-positive neuronal progenitors [83], and het-
erozygous germline mutations of PHOX2B are associated 
with a subset of familial NB [87–90]. These observations 
indicate a central role of PHOX2B in predisposition to 
NB.
In 2013, Pei and collaborators [91] reported that mor-
pholino-mediated PHOX2B deletion in zebrafish leads 
to an impaired sympathetic neuronal differentiation 
of the PSNS. Similarly, the overexpression of an NB-
linked truncation mutation (K155X) [90] or a frameshift 
mutation (676delG) [85] in the presence of endogenous 
PHOX2B leads to a similar block in PSNS differentiation, 
indicating that these variants function in a dominant-
negative manner [91]. This study presents an embryonic 
in  vivo model in which aberrant PHOX2B function-
ing through either allelic deletion or dominant-negative 
mutations promotes an impaired differentiation of sym-
pathetic neuronal progenitor cells. Future experiments 
will investigate in more detail the regulatory relationships 
among the mentioned mutations related to NB.
Aberrant expression of the fgf8 gene in Hagoromo 
mutants
The histological screening of a collection of zebrafish 
insertional mutants revealed that four independent lines 
carrying mutations in the Hagoromo locus develop NB-
like tumors with high penetrance [92]. These fish carry 
viral insertions in the fbxw4 gene that do not affect fbxw4 
expression levels but lead to a sustained and aberrant 
expression of fgf8 after embryogenesis. Notably, tumors 
arising in Hagoromo mutants are quite different from 
human NB, since malignant masses develop in cranial 
ganglia and head of mutant fish. Moreover, tumor cells 
have a neuronal origin (Hu-positive) but do not express 
markers of catecholaminergic differentiation, such as 
TH or DBH, which indicates that these malignant cells 
originate from a different neural lineage than human 
NB. Despite these differences, Hagoromo-derived tumors 
seem to arise through a similar mechanism as in humans 
[92]. Thus, fgf8 appears to function as an oncogene not 
only in numerous malignancies, including prostate and 
breast cancer in mammals [93, 94], but also in NB.
Conclusions
Many cellular and molecular features of NB have been 
identified over the past decades, and some of these 
genetic aberrations are now considered strong and pow-
erful predictors of patient outcome. Nevertheless, there 
is still more complexity behind this pediatric neoplasm, 
and continued advances are needed to translate this 
information into more efficient clinical therapy. Although 
murine and avian models have been used to dissect PSNS 
development and NB pathogenesis [95], zebrafish dis-
plays several advantages, including embryonic optical 
transparency, small size and external development, mak-
ing it easier to follow NCC migration and differentiation. 
Importantly, the generation of new zebrafish models of 
NB can contribute to the knowledge of NB biology and 
genetics. Therefore, the generation and use of zebrafish 
transgenic and mutant lines may provide new opportu-
nities to better understand the biology of NB and to test 
in  vivo potential chemical tumor suppressors through 
high-throughput drug screening. In addition, zebrafish 
models of NB crossed with cell signaling reporter fish 
might be a powerful tool for the in vivo dissection of the 
signaling cascades and molecular mechanisms involved 
in tumor development [96, 97].
Abbreviations
NB: neuroblastoma; PSNS: peripheral sympathetic nervous system; NCC: neu-
ral crest cell; OS: overall survival; CNV: copy number variation; ALK: anaplastic 
lymphoma kinase; EMT: epithelial to mesenchymal transition; hpf: hours 
post-fertilization; BMP: bone morphogenetic factor; dpf: days post-fertilization; 
SCG: superior cervical ganglion; TH: tyrosine hydroxylase; DBH: dopamine 
B-hydroxylase.
Authors’ contributions
DC designed and drafted the manuscript. SC, MO, SA and GPT were involved 
in the discussion. GPT revised the manuscript. All authors read and approved 
the final manuscript.
Author details
1 Neuroblastoma Laboratory, Pediatric Research Institute, Città della Speranza, 
35127 Padua, Italy. 2 Department of Earth, Environmental and Life Sciences, 
(DISTAV), University of Genova, C.so Europa 26, 16132 Genoa, Italy. 3 Unit 
of Cell and Developmental Biology, Department of Biology, University of Pisa, 
S.S.12 Abetone e Brennero 4, 56127 Pisa, Italy. 
Acknowledgements
The present work was supported by Fondazione Italiana per la Lotta al Neuro-
blastoma. The authors are grateful to Dr. Enrico Moro for the critical reading of 
the manuscript.
Competing interests
The authors declare that they have no competing interests.
Funding
The present work was funded by Fondazione Italiana per la Lotta al 
Neuroblastoma.
Received: 11 May 2016   Accepted: 24 October 2016
References
 1. Brodeur GM. Neuroblastoma: biological insight into a clinical enigma. Nat 
Rev Cancer. 2003;3(3):203–16.
 2. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treat-
ment. Hematol Oncol Clin North Am. 2010;24(1):65–86. doi:10.1016/j.
hoc.2009.11.011.
 3. Goessling W, North TE, Zon LI. New waves of discovery: modeling cancer 
in zebrafish. J Clin Oncol. 2007;25(17):2473–9.
Page 8 of 9Corallo et al. Cancer Cell Int  (2016) 16:82 
 4. Stoletov K, Klemke R. Catch of the day: zebrafish as a human cancer 
model. Oncogene. 2008;27(33):4509–20. doi:10.1038/onc.2008.95.
 5. Li P, Lahvic JL, Binder V, et al. Epoxyeicosatrienoic acids enhance 
embryonic haematopoiesis and adult marrow engraftment. Nature. 
2015;523(7561):468–71. doi:10.1038/nature14569.
 6. Lessman CA. The developing zebrafish (Danio rerio): a vertebrate model 
for high-throughput screening of chemical libraries. Birth Defects Res C 
Embryo Today. 2011;93(3):268–80. doi:10.1002/bdrc.20212.
 7. Cotterill SJ, Parker L, More L, et al. Neuroblastoma: changing incidence 
and survival in young people aged 0–24 years. A report from the North of 
England Young Persons’ Malignant Disease Registry. Med Pediatr Oncol. 
2001;36(1):231–4.
 8. Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in 
European children (1978–1997): report from the Automated Childhood 
Cancer Information System project. Eur J Cancer. 2006;42(13):2081–91.
 9. Scaruffi P, Coco S, Cifuentes F, et al. Identification and characterization of 
DNA imbalances in neuroblastoma by high-resolution oligonucleotide 
array comparative genomic hybridization. Cancer Genetic Cytogenet. 
2007;177(1):20–9.
 10. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 
influence susceptibility to high-risk neuroblastoma. Nat Genet. 
2009;41(6):718–23. doi:10.1038/ng.374.
 11. Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 asso-
ciated with neuroblastoma. Nature. 2009;459(7249):987–91. doi:10.1038/
nature08035.
 12. Schwab M. MYCN in neuronal tumours. Cancer Lett. 2004;204(2):179–87.
 13. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk 
stratification. Curr Opin Pediatr. 2005;17(1):7–13.
 14. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major 
familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–
5. doi:10.1038/nature07261.
 15. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lym-
phoma kinase overexpression in poor prognosis neuroblastoma patients. 
Cancer Res. 2009;69(18):7338–46. doi:10.1158/0008-5472.CAN-08-4419.
 16. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide 
a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975–8. 
doi:10.1038/nature07397.
 17. Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as 
a neuroblastoma oncogene. Nature. 2011;469(7392):216–20.
 18. Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus 
associated with clinically aggressive neuroblastoma. N Engl J Med. 
2008;358(24):2585–93. doi:10.1056/NEJMoa0708698.
 19. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk 
neuroblastoma. Nat Genet. 2013;45(3):279–84. doi:10.1038/ng.2529.
 20. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblas-
toma identifies chromothripsis and defects in neuritogenesis genes. 
Nature. 2012;483(7391):589–93. doi:10.1038/nature10910.
 21. Zhu S, Lee JS, Guo F, et al. Activated ALK collaborates with MYCN in neu-
roblastoma pathogenesis. Cancer Cell. 2012;21(3):362–73. doi:10.1016/j.
ccr.2012.02.010.
 22. Zhu S, Look TA. Neuroblastoma and its zebrafish model. Adv Exp Med 
Biol. 2016;916:451–78. doi:10.1007/978-3-319-30654-4_20.
 23. Coulon A, Flahaut M, Muhlethaler-Mottet A, et al. Functional sphere 
profiling reveals the complexity of neuroblastoma tumor-initiating cell 
model. Neoplasia. 2011;13(10):991–1004.
 24. Hansford LM, McKee AE, Zhang L, et al. Neuroblastoma cells isolated from 
bone marrow metastases contain a naturally enriched tumor-initiating 
cell. Cancer Res. 2007;67(23):11234–43.
 25. Khanna C, Jaboin JJ, Drakos E, et al. Biologically relevant orthotopic 
neuroblastoma xenograft models: primary adrenal tumor growth and 
spontaneous distant metastasis. In vivo. 2002;16(2):77–85.
 26. Patterson DM, Shohet JM, Kim ES. Preclinical models of pediatric solid 
tumors (neuroblastoma) and their use in drug discovery. Curr Protoc 
Pharmacol. 2011. Chapter 14:Unit 14.17. doi: 10.1002/0471141755.
ph1417s52.
 27. Teitz T, Stanke JJ, Federico S, et al. Preclinical models for neuroblastoma: 
establishing a baseline for treatment. PLoS ONE. 2011;6(4):e19133. 
doi:10.1371/journal.pone.0019133.
 28. Bate-Eya LT, Ebus ME, Koster J, et al. Newly-derived neuroblastoma 
cell lines propagated in serum-free media recapitulate the genotype 
and phenotype of primary neuroblastoma tumours. Eur J Cancer. 
2014;50(3):628–37. doi:10.1016/j.ejca.2013.11.015.
 29. Joseph JM, Gross N, Lassau N, et al. In vivo ecographic evidence 
of tumoral vascularization and microenvironment interactions in 
metastatic orthotopic human neuroblastoma xenografts. Int J Cancer. 
2005;113(6):881–90.
 30. Braekeveldt N, Wigerup C, Gisselsson D, et al. Neuroblastoma patient-
derived orthotopic xenografts retain metastatic patterns and geno- and 
phenotypes of patient tumours. Int J Cancer. 2015;136(5):E252–61. 
doi:10.1002/ijc.29217.
 31. Becher OJ, Holland EC. Genetically engineered models have advantages 
over zenografts for preclinical studies. Cancer Res. 2006;66(7):3355–8.
 32. Weiss WA, Aldape K, Mohapatra G, et al. Targeted expression of MYCN 
causes neuroblastoma in transgenic mice. EMBO J. 1997;16(11):2985–95.
 33. Moore HC, Wood KM, Jackson MS, et al. Histological profile of tumours 
from MYCN transgenic mice. J Clin Pathol. 2008;61(10):1098–103.
 34. Weiss WA, Godfrey T, Francisco C, et al. Genome-wide screen for 
allelic imbalance on a mouse model for neuroblastoma. Cancer Res. 
2000;60(9):2483–7.
 35. Hackett CS, Hodgson JG, Law ME, et al. Genome-wide array CGH analysis 
of murine neuroblastoma reveals distinct genomic aberrations which 
parallel those in humans tumors. Cancer Res. 2003;63(17):5266–73.
 36. Norris MD, Burkhart CA, Marshall GM, et al. Expression of N-myc and MRP 
genes and their relationship to N-myc gene disage and tumor formation 
in a murine neuroblastoma model. Med Pediatr Oncol. 2000;35(6):585–9.
 37. Terrile M, Bryan K, Vaughan L, et al. miRNA expression profiling of 
the murine TH-MYCN neuroblastoma model reveals similarities with 
human tumors and identifies novel candidate miRNAs. PLoS ONE. 
2011;6(12):e28356. doi:10.1371/journal.pone.0028356.
 38. Molenaar JJ, Domingo-Fernández R, Ebus ME, et al. LIN28B induces neu-
roblastoma and enhances MYCN levels via let-7 suppression. Nat Genet. 
2012;44(11):1199–206. doi:10.1038/ng.2436.
 39. Heukamp LC, Thor T, Schramm A, et al. Targeted expression of mutated 
ALK induces neuroblastoma in transgenic mice. Sci Transl Med. 
2012;4(141):141ra91. doi:10.1126/scitranslmed.3003967.
 40. Marshall GM, Carter DR, Cheung BB, et al. The prenatal origins of cancer. 
Nat Rev Cancer. 2014;14(4):277–89. doi:10.1038/nrc3679.
 41. Le Douarin NM, Kalcheim C. The neural crest. Cambridge: Cambridge 
University Press; 1999.
 42. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insight from develop-
ment. Development. 2012;139(19):3471–86.
 43. Acloque H, Adams MS, Fishwick K. Epithelial-mesenchymal transitions: 
the importance of changing cell state in development and disease. J Clin 
Invest. 2009;119(6):1438–49. doi:10.1172/JCI38019.
 44. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroad 
of development and tumor metastasis. Dev Cell. 2008;14(6):818–29. 
doi:10.1016/j.devcel.2008.05.009.
 45. Pasquier J, Abu-Kaoud N, Al Thani H, et al. Epithelial to mesenchy-
mal transition in a clinical perspective. J Oncol. 2015;2015:792182. 
doi:10.1155/2015/792182.
 46. Nozato M, Kaneko S, Nakagawara A, et al. Epithelial-mesenchymal 
transition-related gene expression as a new prognostic marker for neuro-
blastoma. Int J Oncol. 2013;42(1):134–40. doi:10.3892/ijo.2012.1684.
 47. Kelsh RN, Harris ML, Colanesi S, et al. Stripes and belly-spots—a review 
of pigment cell morphogenesis in vertebrates. Semin Cell Dev Biol. 
2009;20(1):90–104. doi:10.1016/j.semcdb.2008.10.001.
 48. Serbedzija GN, Fraser SE, Bronner-Fraser M. Pathways of trunk neural crest 
cell migration in the mouse embryo as revealed by vital dye labelling. 
Development. 1990;108(4):605–12.
 49. Shtukmaster S, Schier MC, Huber K, et al. Sympathetic neurons and chro-
maffin cells share a common progenitor in the neural crest in vivo. Neural 
Dev. 2013;8:12. doi:10.1186/1749-8104-8-12.
 50. Theveneau E, Mayor R. Neural crest delamination and migration: from 
epithelium-to-mesenchyme transition to collective cell migration. Dev 
Biol. 2012;366(1):34–54. doi:10.1016/j.ydbio.2011.12.041.
 51. Dutt S, Matasci M, Sommer L, et al. Guidance of neural crest cell migra-
tion: the inhibitory function of the chondroitin sulfate proteoglycan, 
versican. ScientificWorldJournal. 2006;6:1114–7.
 52. Perris R, Perissinotto D. Role of the extracellular matrix during neural crest 
cell migration. Mech Dev. 2000;95(1–2):3–21.
Page 9 of 9Corallo et al. Cancer Cell Int  (2016) 16:82 
 53. Rorth P. Collective cell migration. Annu Rev Cell Dev Biol. 2009;25:407–29. 
doi:10.1146/annurev.cellbio.042308.113231.
 54. An M, Luo R, Henion PD. Differentiation and maturation of zebrafish 
dorsal root and sympathetic ganglion neurons. J Comp Neurol. 
2002;446(3):267–75.
 55. Raible DW, Eisen JS. Restriction of neural crest cell fate in the trunk of the 
embryonic zebrafish. Development. 1994;120(3):495–503.
 56. Dutton KA, Pauliny A, Lopes SS, et al. Zebrafish colourless encodes sox10 
and specifies non-ectomesenchymal neural crest fates. Development. 
2001;128(21):4113–25.
 57. Betters E, Liu Y, Kjaeldgaard A, Sundstrom E, et al. Analysis of early human 
neural crest development. Dev Biol. 2010;344(2):578–92. doi:10.1016/j.
ydbio.2010.05.012.
 58. Rubinstein AL, Lee D, Luo R, et al. Genes dependent on zebrafish cyclops 
function identified by AFLP differential gene expression screen. Genesis. 
2000;26(1):86–97.
 59. Britsch S, Li L, Kirchhoff S, Theuring F, et al. The ErbB2 and ErbB3 recep-
tors and their ligand, neuregulin-1, are essential for development of the 
sympathetic nervous system. Genes Dev. 1998;12(12):1825–36.
 60. Morris JK, Lin W, Hauser C, et al. Rescue of the cardiac defect in ErbB2 
mutant mice reveals essential roles of ErbB2 in peripheral nervous system 
development. Neuron. 1999;23(2):273–83.
 61. Honjo Y, Kniss J, Eisen JS. Neuregulin-mediated ErbB3 signaling is required 
for formation of zebrafish dorsal root ganglion neurons. Development. 
2008;135(15):2615–25. doi:10.1242/dev.022178.
 62. Britsch S, Goerich DE, Riethmacher D, et al. The transcription factor 
Sox10 is a key regulator of peripheral glial development. Genes Dev. 
2001;15(1):66–78.
 63. Paratore C, Goerich DE, Suter U, et al. Survival and glial fate acquisition of 
neural crest cells are regulated by an interplay between the transcrip-
tion factor Sox10 and extrinsic combinatorial signaling. Development. 
2001;128(20):3949–61.
 64. Prasad MK, Reed X, Gorkin DU, et al. SOX10 directly modulates ERBB3 
transcription via an intronic neural crest enhancer. BMC Dev Biol. 
2011;11:40. doi:10.1186/1471-213X-11-40.
 65. Charron J, Malynn BA, Fisher P, et al. Embryonic lethality in mice 
homozygous for a targeted disruption of the N-myc gene. Genes Dev. 
1992;6(12A):2248–57.
 66. Sawai S, Shimono A, Wakamatsu Y, et al. Defects of embryonic organo-
genesis resulting from targeted disruption of the N-myc gene in the 
mouse. Development. 1993;117(4):1445–55.
 67. Stanton BR, Perkins AS, Tessarollo L, et al. Loss of N-myc function results 
in embryonic lethality and failure of the epithelial component of the 
embryo to develop. Genes Dev. 1992;6(12A):2235–47.
 68. Kasemeier-Kulesa JC, Bradley R, Pasquale EB, Lefcort F, et al. Eph/ephrins 
and N-cadherin coordinate to control the pattern of sympathetic ganglia. 
Development. 2006;133(24):4839–47.
 69. Saito D, Takase Y, Murai H, et al. The dorsal aorta initiates a molecu-
lar cascade that instructs sympatho-adrenal specification. Science. 
2012;336(6088):1578–81.
 70. Yao KM, Samson ML, Reeves R, et al. Gene elav of Drosophila mela-
nogaster: a prototype for neuronal-specific RNA binding protein 
gene family that is conserved in flies and humans. J Neurobiol. 
1993;24(6):723–39.
 71. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 
2007;369(9579):2106–20.
 72. Guillemot F, Joyner AL. Dynamic expression of the murine achaete-
scute homologue mash-1 in the developing nervous system. Mech Dev. 
1993;42(3):171–85.
 73. Guo S, Brush J, Teraoka H, et al. Development of noradrenergic neurons 
in the zebrafish hindbrain requires BMP, FGF8, and the homeodomain 
protein soulless/Phox2a. Neuron. 1999;24(3):555–66.
 74. Lucas ME, Muller F, Rudiger R, et al. The bHLH transcription factor hand2 
is essential for noradrenergic differentiation of sympathetic neurons. 
Development. 2006;133(20):4015–24.
 75. Pattyn A, Morin X, Cremer H, et al. The homeobox gene Phox2b is essen-
tial for the development of autonomic neural crest derivatives. Nature. 
1999;399(6734):366–70.
 76. Holzschuh J, Barrallo-Gimeno A, Ettl AK, et al. Noradrenergic neurons 
in the zebrafish hindbrain are induced by retinoic acid and require 
tfap2a for expression of the neurotransmitter phenotype. Development. 
2003;130(23):5741–54.
 77. Knight RD, Nair S, Nelson SS, et al. Lockjaw encodes a zebrafish 
tfap2a required for early neural crest development. Development. 
2003;130(23):5755–68.
 78. Huber K. The sympathoadrenal cell lineage: specification, diversification, 
and new perspectives. Dev Biol. 2006;298(2):335–43.
 79. Clay MR, Halloran MC. Control of neural crest cell behavior and migration: 
insights from live imaging. Cell Adh Migr. 2010;4(4):586–94. doi:10.4161/
cam.4.4.12902.
 80. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal 
tumor initiation: distinct roles for MycN expression and MYCN amplifica-
tion. Prot Natl Acad Sci USA. 2004;101(34):12664–9.
 81. Wartiovaara K, Barnabe-Heider F, Miller FD, et al. N-myc promotes survival 
and induces S-phase entry of postmitotic sympathetic neurons. J Neuro-
sci. 2002;22(3):815–24.
 82. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogen-
esis of peripheral neuroblastic tumors. Oncogene. 2010;29(11):1566–79. 
doi:10.1038/onc.2009.518.
 83. Alam G, Cui H, Shi H, et al. MYCN promotes the expansion of Phox2B-
positive neuronal progenitors to drive neuroblastoma development. Am 
J Pathol. 2009;175(2):856–66. doi:10.2353/ajpath.2009.090019.
 84. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in 
neuroblastoma. Nature. 2008;455(7215):971–4. doi:10.1038/nature07399.
 85. He S, Mansour MR, Zimmerman MW, et al. Synergy between loss of NF1 
and overexpression of MYCN in neuroblastoma is mediated by the GAP-
related domain. ELife. 2016;5:e14713. doi:10.7554/eLife.14713.
 86. Pattyn A, Morin X, Cremer H, et al. Expression and interactions of the two 
closely related homeobox genes Phox2a and Phox2b during neurogen-
esis. Development. 1997;124:4065–75.
 87. Longo L, Borghini S, Schena F, et al. PHOX2A and PHOX2B genes 
are highly co-expressed in human neuroblastoma. Int J Oncol. 
2008;33(5):985–91.
 88. Perri P, Bachetti T, Longo L, et al. PHOX2B mutations and genetic predis-
position to neuroblastoma. Oncogene. 2005;24(18):3050–3.
 89. Mosse YP, Laudenslager M, Khazi D, et al. Germline PHOX2B mutation in 
hereditary neuroblastoma. Am J Hum Genet. 2004;75(4):727–30.
 90. Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of 
the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J 
Hum Genet. 2004;74(4):761–4.
 91. Pei D, Luther W, Wang W, et al. Distinct neuroblastoma-associated 
alterations of PHOX2B impair sympathetic neuronal differentiation in 
zebrafish models. PLoS Genet. 2013;9(6):e1003533. doi:10.1371/journal.
pgen.1003533.
 92. Amsterdam A, Lai K, Komisarczuk AZ, et al. Zebrafish Hagoromo mutants 
up-regulate fgf8 postembryonically and develop neuroblastoma. Mol 
Cancer Res. 2009;7(6):841–50. doi:10.1158/1541-7786.MCR-08-0555.
 93. Zhong C, Saribekyan G, Liao CP, et al. Cooperation between FGF8b over-
expression and PTEN deficiency in prostate tumorigenesis. Cancer Res. 
2006;66(4):2188–94. doi:10.1158/0008-5472.CAN-05-3440.
 94. Liu F, You X, Wang Y, et al. The oncoprotein HBXIP enhances angiogen-
esis and growth of breast cancer through modulating FGF8 and VEGF. 
Carcinogenesis. 2014;35(5):1144–53. doi:10.1093/carcin/bgu021.
 95. Kasemeier-Kulesa JC, Kulesa PM, Lefcort F. Imaging neural crest dynamics 
during formation of dorsal root ganglia and sympathetic ganglia. Devel-
opment. 2005;132:235–45. doi:10.1242/dev.01553.
 96. Moro E, Vettori A, Porazzi P, et al. Generation and application of signaling 
pathway reporter lines in zebrafish. Mol Genet Genomics. 2013;288(5–
6):231–42. doi:10.1007/s00438-013-0750-z.
 97. Schiavone M, Rampazzo E, Casari A, et al. Zebrafish reporter lines reveal 
in vivo signaling pathways activities involved in pancreatic cancer. Dis 
Model Mech. 2014;7(7):883–94. doi:10.1242/dmm.014969.
